janus kinase 3

Summary

Summary: A Janus kinase subtype that is predominantly expressed in hematopoietic cells. It is involved in signaling from a broad variety of CYTOKINE RECEPTORS including ones that utilize the INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT.

Top Publications

  1. Babon J, Lucet I, Murphy J, Nicola N, Varghese L. The molecular regulation of Janus kinase (JAK) activation. Biochem J. 2014;462:1-13 pubmed publisher
    ..These recent studies highlight the diversity of regulatory mechanisms utilized by the JAK family to maintain signalling fidelity, and suggest alternative therapeutic strategies to complement existing ATP-competitive kinase inhibitors. ..
  2. Wang S, Iwata S, Nakayamada S, Sakata K, Yamaoka K, Tanaka Y. Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro. Ann Rheum Dis. 2014;73:2213-5 pubmed publisher
  3. Wang Y, Cui X, Chuang Y, Chen S. Janus Kinase 3, a Novel Regulator for Smooth Muscle Proliferation and Vascular Remodeling. Arterioscler Thromb Vasc Biol. 2017;37:1352-1360 pubmed publisher
    ..The objective of this study is to determine the role and mechanism of Janus kinase 3 (JAK3) in vascular remodeling and SMC proliferation...
  4. Hynes J, Wu H, Kempson J, Duan J, Lu Z, Jiang B, et al. Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitors. Bioorg Med Chem Lett. 2017;27:3101-3106 pubmed publisher
    ..X-ray co-crystal structure determination confirmed the presumed inhibitor binding orientation in JAK3. Efforts to reduce hERG channel inhibition will be described. ..
  5. Wang X, Wang Y, Wang Y, Sun L, Gooneratne R. Preparation of T-2-glucoronide with Rat Hepatic Microsomes and Its Use along with T-2 for Activation of the JAK/STAT Signaling Pathway in RAW264.7 Cells. J Agric Food Chem. 2017;65:4811-4818 pubmed publisher
    ..Overall, the results show that T-2-GlcA was somewhat toxic, but activation of the JAK/STAT pathway in RAW264.7 was higher by T-2. ..
  6. Forster M, Gehringer M, Laufer S. Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting. Bioorg Med Chem Lett. 2017;27:4229-4237 pubmed publisher
    ..Since one of these inhibitors is currently under evaluation in phase II clinical studies against several inflammatory disorders, it will soon become apparent whether selective JAK3 inhibition translates into clinical efficacy. ..
  7. Zhong L, Wang W, Ma M, Gou L, Tang X, Song H. Chronic active Epstein-Barr virus infection as the initial symptom in a Janus kinase 3 deficiency child: Case report and literature review. Medicine (Baltimore). 2017;96:e7989 pubmed publisher
    ..an increasing number of atypical primary immunodeficiency (PID) patients have been discovered, including Janus kinase 3 (JAK3) gene deficiency...
  8. O Shea J. Targeting the Jak/STAT pathway for immunosuppression. Ann Rheum Dis. 2004;63 Suppl 2:ii67-ii71 pubmed
  9. Kremer J, Li Z, Hall S, Fleischmann R, Genovese M, Martin Mola E, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013;159:253-61 pubmed publisher
    ..The ability to assess drug combinations other than tofacitinib plus methotrexate was limited. Tofacitinib improved disease control in patients with active RA despite treatment with nonbiologic DMARDs, primarily methotrexate. Pfizer. ..

More Information

Publications15

  1. Mitiushova E, Shatrova A, Zenin V, Aksenov N, Marakhova I. [The STAT5 signaling in the expression of alpha-subunit of interleukin-2 receptor in human blood lymphocytes]. Tsitologiia. 2013;55:421-9 pubmed
    ..It has been concluded that JAK3/STAT5 signaling via IL-2 receptor is necessary to maintain the long-term expression of the high-affinity αβγ(c)-receptor of IL-2 and optimal proliferation of HBL. ..
  2. Edwards J. Renal fibrosis: Activation of JAK3/STAT6 contributes to the development of renal fibrosis. Nat Rev Nephrol. 2015;11:445 pubmed publisher
  3. Lopez J, Angulo J, Martin A, Sanchez Chapado M, González Corpas A, Colás B, et al. A DNA hypermethylation profile reveals new potential biomarkers for the evaluation of prognosis in urothelial bladder cancer. APMIS. 2017;125:787-796 pubmed publisher
    ..Combined hypermethylation of SOX1, PITX2, or CSPG2 signals patients at higher risk of death from bladder cancer. ..
  4. Mishra J, Das J, Kumar N. Janus kinase 3 regulates adherens junctions and epithelial mesenchymal transition through ?-catenin. J Biol Chem. 2017;292:16406-16419 pubmed publisher
    ..We reported previously that Janus kinase 3, a non-receptor tyrosine kinase, plays a crucial role in AJ formation through its interaction with ?-catenin...
  5. Liu L, Strassner J, Refat M, Harris J, King B. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol. 2017;77:675-682.e1 pubmed publisher
    ..These results support a model wherein JAK inhibitors suppress T cell mediators of vitiligo and light exposure is necessary for stimulation of melanocyte regeneration. ..
  6. Kempson J, Ovalle D, Guo J, Wrobleski S, Lin S, Spergel S, et al. Discovery of highly potent, selective, covalent inhibitors of JAK3. Bioorg Med Chem Lett. 2017;27:4622-4625 pubmed publisher
    ..The design was based on crystal structure information and a comparative study of several electrophilic warheads. ..